Literature DB >> 7173186

Pharmacokinetic studies of amoxicillin, potassium clavulanate and their combination.

G Witkowski, H Lode, G Höffken, P Koeppe.   

Abstract

Pharmacokinetic parameters after oral administration of 500 mg amoxicillin, 125 mg potassium clavulanate and 625 mg of their combination (augmentin) were determined in a randomized crossover study in ten healthy volunteers. The absolute bioavailability of amoxicillin (AUCoral/AUCi.v.) was 0.70 +/- 0.12. The mean maximum serum concentration of amoxicillin was 6.5 +/- 1.6 mg/l after administration alone and 6.5 +/- 1.4 mg/l after administration in combination. The respective values for potassium clavulanate were 3.4 +/- 1.4 mg/l and 2.8 +/- 1.1 mg/l. With both substances there was no significant difference between the pharmacokinetic parameters after administration alone and in combination. The AUC for amoxicillin was 19.5 +/- 5.4 h x mg/l after administration alone and 23.2 +/- 10.6 h x mg/l after administration in combination. The respective value for potassium clavulanate were 7.8 +/- 3.2 h x mg/l and 7.3 +/- 2.0 h x mg/l.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7173186     DOI: 10.1007/bf02019714

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  12 in total

1.  In vitro study of clavulanic acid in combination with penicillin, amoxycillin, and carbenicillin.

Authors:  R Wise; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

2.  Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus.

Authors:  C Reading; M Cole
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

3.  Comparative clinical pharmacology of three ampicillins and amoxicillin administered orally.

Authors:  H Lode; P Janisch; G Küpper; H Weuta
Journal:  J Infect Dis       Date:  1974-06       Impact factor: 5.226

4.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

5.  Clavulanic acid and amoxycillin: a clinical, bacteriological, and pharmacological study.

Authors:  A P Ball; A M Geddes; P G Davey; I D Farrell; G R Brookes
Journal:  Lancet       Date:  1980-03-22       Impact factor: 79.321

6.  Clinical efficacy and tolerance of Augmentin in soft tissue infection.

Authors:  A P Ball; S Mehtar; A Watson
Journal:  J Antimicrob Chemother       Date:  1982-07       Impact factor: 5.790

7.  Human pharmacokinetics and CSF penetration of clavulanic acid.

Authors:  R Münch; R Lüthy; J Blaser; W Siegenthaler
Journal:  J Antimicrob Chemother       Date:  1981-07       Impact factor: 5.790

8.  Pharmacokinetics of bacampicillin compared with those of ampicillin, pivampicillin, and amoxycillin.

Authors:  J Sjövall; L Magni; T Bergan
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

9.  Kinetic studies on the inactivation of Escherichia coli RTEM beta-lactamase by clavulanic acid.

Authors:  J Fisher; R L Charnas; J R Knowles
Journal:  Biochemistry       Date:  1978-05-30       Impact factor: 3.162

10.  [Studies on the pharmacokinetics of amoxicillin after intravenous, intramuscular and oral administration (author's transl)].

Authors:  A Dalhoff; P Koeppe; D von Kobyletzki
Journal:  Arzneimittelforschung       Date:  1981
View more
  6 in total

Review 1.  New formulations of amoxicillin/clavulanic acid: a pharmacokinetic and pharmacodynamic review.

Authors:  Amparo Sánchez Navarro
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.

Authors:  K M Deppermann; H Lode; G Höffken; G Tschink; C Kalz; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

3.  Pharmacokinetics of sulbactam and ampicillin following oral administration of sultamicillin with probenecid.

Authors:  A M Emmerson; D A Cox; L J Lees
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

4.  A Dual-Biotic System for the Concurrent Delivery of Antibiotics and Probiotics: In Vitro, Ex Vivo, In Vivo and In Silico Evaluation and Correlation.

Authors:  Mershen Govender; Yahya E Choonara; Sandy van Vuuren; Pradeep Kumar; Lisa C du Toit; Kennedy Erlwanger; Viness Pillay
Journal:  Pharm Res       Date:  2016-09-06       Impact factor: 4.200

Review 5.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

6.  Comparative pharmacokinetics of sulbactam/ampicillin and clavulanic acid/amoxycillin in human volunteers.

Authors:  B Hampel; H Lode; G Bruckner; P Koeppe
Journal:  Drugs       Date:  1988       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.